bufoler easyhaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort forte turbuhaler 9+320 mikrog./dosis inhalationspulver
abacus medicine a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog./dosis
symbicort turbohaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
paranova danmark a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
bufar easyhaler 4.5+80 mikrog/dosis inhalationspulver
orion corporation - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4.5+80 mikrog/dosis
airbufo forspiro 160+4,5 mikrogram/dosis inhalationspulver, afdelt
sandoz a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver, afdelt - 160+4,5 mikrogram/dosis
symbicort 2,25+80 mikrog/dosis inhalationsspray, suspension
astrazeneca a/s - budesonid, formoterolfumarat dihydrat - inhalationsspray, suspension - 2,25+80 mikrog/dosis
jorveza
dr. falk pharma gmbh - budesonide - esophageal sygdomme - antidiarrémidler, tarm antiinflammatorisk / antiinfective agenter - jorveza er indiceret til behandling af eosinofiløsofagitis (eoe) hos voksne (over 18 år).
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).